Amedisys (AMED) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amedisys Reports Second Quarter 2021 Financial Results, Closing of Contessa Acquisition, Expansion of Credit Facility and Authorization of New $100 Million Share Repurchase Program
August 4, 2021 4:05 PM EDTBATON ROUGE, La., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2021.
Three-Month Periods Ended June 30, 2021 and 2020
Net service revenue increased $79.2Â million to $564.2Â million compared to $485.0Â million in 2020.Net income attributable to Amedisys, Inc. of $80.1Â million compared to $34.7Â million in 2020.Net income attributable to Amedisys, Inc. per diluted share of $2.43 compared to $1.04 in 2020.Adjusted Quarterly Results*
Adjusted EBITDA of $83.8Â million compared to $66.4Â million in 2020.Adjusted net service revenue of $557.6Â million compared to $485.0Â million in... More